These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 17488734)
1. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Helbling D; Borner M Ann Oncol; 2007 May; 18(5):963-4. PubMed ID: 17488734 [No Abstract] [Full Text] [Related]
2. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398 [No Abstract] [Full Text] [Related]
3. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280 [TBL] [Abstract][Full Text] [Related]
4. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Saif MW; Peccerillo J; Potter V Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300 [TBL] [Abstract][Full Text] [Related]
5. Successful cetuximab therapy after failure of panitumumab rechallenge in a patient with metastatic colorectal cancer: restoration of drug sensitivity after anti-EGFR monoclonal antibody-free interval. Hata A; Katakami N; Kitajima N J Gastrointest Cancer; 2014 Dec; 45(4):506-7. PubMed ID: 24880984 [No Abstract] [Full Text] [Related]
6. Successful treatment with the fully human antibody panitumumab after a severe infusion reaction with cetuximab. Brugger W Tumori; 2010; 96(3):473-7. PubMed ID: 20845811 [TBL] [Abstract][Full Text] [Related]
7. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Heun J; Holen K Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202 [TBL] [Abstract][Full Text] [Related]
8. Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer. Cartwright TH; Genther R Clin Colorectal Cancer; 2008 May; 7(3):202-3. PubMed ID: 18621639 [TBL] [Abstract][Full Text] [Related]
9. Different patterns of toxicity after sequential administration of two anti-EGFR monoclonal antibodies. López-Gómez M; Gómez-Raposo C; Sereno M; Zambrana F; Casado E Clin Transl Oncol; 2010 Nov; 12(11):775-7. PubMed ID: 20974572 [TBL] [Abstract][Full Text] [Related]
10. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. Funakoshi T; Suzuki M; Tamura K Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497 [TBL] [Abstract][Full Text] [Related]
11. Panitumumab a novel drug in cancer treatment. Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813 [TBL] [Abstract][Full Text] [Related]
12. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Langerak A; River G; Mitchell E; Cheema P; Shing M Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897 [TBL] [Abstract][Full Text] [Related]
13. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Zhang W; Gordon M; Lenz HJ Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669 [TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Xu W; Jing H; Zhang F Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782 [TBL] [Abstract][Full Text] [Related]
15. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Ouwerkerk J; Boers-Doets C Eur J Oncol Nurs; 2010 Sep; 14(4):337-49. PubMed ID: 20580896 [TBL] [Abstract][Full Text] [Related]
16. [New developments in immunotherapy for digestive system diseases]. Imai K Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1901-7. PubMed ID: 16223155 [No Abstract] [Full Text] [Related]
17. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab. Nielsen DL; Pfeiffer P; Jensen BV Ann Oncol; 2009 Apr; 20(4):798. PubMed ID: 19254943 [No Abstract] [Full Text] [Related]
18. [Molecular target therapy for colonic neoplasms]. Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595 [No Abstract] [Full Text] [Related]
19. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140 [TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. Lee D Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399 [No Abstract] [Full Text] [Related] [Next] [New Search]